Infuzijske reakcije po parenteralni aplikaciji citostatikov na Onkološkem inštitutu Ljubljana med leti 2019-2023
Infusion reactions following parenteral administration of cytostatic drugs at the Institute of Oncology Ljubljana between 2019 and 2023

slovenian

2025

volume 76, issue 1

Slovensko farmacevtsko društvo
(Obvezni izvod spletne publikacije)

Several anticancer therapies administered by the parenteral route carry a risk for infusion reactions, which are common cause of treatment interruption for patients with cancer. The study included all patients who experienced an infusion reaction during parenteral administration of chemotherapy during this period. In patients who received 14 different cytostatic drugs, infusion reactions occurred in 403 cases. The highest incidence of infusion reactions (7.42%) was observed with pegylated liposomal doxorubicin, and the lowest with cyclophosphamide (0.06%). Infusion reactions occurred most frequently during the first or second cycle of therapy with anthracyclines and taxanes and in later cycles with platinum compounds. For most therapeutic agents, except for platinum compounds, patients were able to continue chemotherapy on the same day after the onset of an infusion reaction, with recurrence being rare.

06.05.2025